Jupiter Topco LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX

Jupiter Topco LLC purchased a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, Holdings Channel reports. The firm purchased 1,046,000 shares of the company’s stock, valued at approximately $6,851,000.

A number of other large investors also recently bought and sold shares of the stock. Persistent Asset Partners Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $25,000. BlackRock Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth $40,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth $71,000. Bank of America Corp DE raised its position in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the period. Finally, Aptus Capital Advisors LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter worth $76,000.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $6.68 on Monday. The firm’s fifty day simple moving average is $6.60 and its 200 day simple moving average is $7.03. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals Inc. has a twelve month low of $5.12 and a twelve month high of $9.32. The firm has a market capitalization of $434.33 million, a price-to-earnings ratio of -6.55 and a beta of 1.08.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, equities research analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on EPRX. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a “buy” rating and a $25.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.